Skip to content
Review Open access

Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions

Sep 2026 · Journal of clinical pharmacology · Vol 66 · 0 citations · 76 references
Medicine

TL;DR

This review outlines the historical development and conceptual foundations of QSP and summarizes representative clinical applications spanning early, mid, and late development, and considers emerging challenges and opportunities for QSP adoption.

Abstract

Quantitative systems pharmacology (QSP) integrates mechanistic representations of biology with quantitative pharmacology to support decision‑making across the drug development continuum. Over the past two decades, QSP has evolved from an exploratory research activity into an established component of model‑informed drug development (MIDD), particularly in settings where system‑level interactions complicate the interpretation of exposure–response relationships or where direct clinical data are limited. This review outlines the historical development and conceptual foundations of QSP and summarizes representative clinical applications spanning early, mid, and late development. Examples highlight how QSP is used to support mechanism‐based dose and regimen selection, optimization of combination strategies, biomarker‑informed patient stratification, and lifecycle management decisions. We also discuss considerations for rigor, credibility, and trustworthiness in alignment with the ICH M15 framework, emphasizing clearly defined questions of interest, context of use, and proportional, decision‐driven evaluation of assumptions and uncertainty. Finally, we consider emerging challenges and opportunities for QSP adoption, including reuse of platform models, integration of multi‐omics data, and selective incorporation of AI‐enabled methods within mechanistically interpretable frameworks.

Read PDF

Similar papers

Review Open access Sep 2026

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and...

Karen Rowland Yeo, P. H. van der Graaf · 0 citations
Open access Sep 2026

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision‐making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitati...

T. Klabunde, Ramon Hernandez, P. H. van der Graaf et al. · 0 citations
Review Open access Sep 2026

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

In silico and in vitro NAMs including quantitative systems pharmacology (QSP) modeling for opioid overdose scenarios, (quantitative) structure–activity relationship ((Q)SAR) modeling for toxicity prediction and drug–drug interaction assessment, and multi‐omics approaches for pharmacodynamic biomarker discovery are desc...

Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi et al. · 0 citations
Open access Sep 2026

From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate.

Regulatory science increasingly recognizes that comparative efficacy studies may provide limited additional certainty to biosimilar development when high-resolution analytical, functional, and pharmacokinetic data robustly demonstrate similarity to the reference product. Modern structural and functional assays, combine...

Björn Capsius, Marija Pesic, R. Niyazov et al. · 0 citations
Review Aug 2026

Pharmacogenomic and Medicinal Chemistry Perspectives on Off-label Drug Use.

INTRODUCTION Off-label drug use (OLDU) is frequent in populations insufficiently represented in clinical trials, including pediatrics, rare diseases, and psychiatry. Although it broadens therapeutic options, uncertainty regarding safety and response remains a central concern. Physical chemistry properties influence dru...

Mariana Meira Scudeler, Isadora Renck Scherer, Gabriel Vaisam Castro et al. · 0 citations
Review Open access Sep 2026

Harnessing Quantitative Medicine to Advance Oncology Drug Development

ABSTRACT Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quant...

Benjamin Wu, Kenta Yoshida, P. Chanu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.